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Background: γ-Glutamyl transferase (GGT) is a well-known marker of chronic alcohol consumption or hepatobiliary diseases. A 
number of studies have demonstrated that serum levels of GGT are independently associated with cardiovascular and metabolic 
disorders. The purpose of this study was to test if serum GGT levels are associated with bone mineral density (BMD) in Korean 
adults.
Methods: A total of 462 subjects (289 men and 173 women), who visited Severance Hospital for medical checkup, were included 
in this study. BMD was measured using dual energy X-ray absorptiometry. Cross-sectional association between serum GGT and 
BMD was evaluated.
Results: As serum GGT levels increased from the lowest tertile (tertile 1) to the highest tertile (tertile 3), BMD decreased after 
adjusting for confounders such as age, body mass index, amount of alcohol consumed, smoking, regular exercise, postmenopaus-
al state (in women), hypertension, diabetes mellitus, and hypercholesterolemia. A multiple linear regression analysis showed a 
negative association between log-transformed serum GGT levels and BMD. In a multiple logistic regression analysis, tertile 3 of 
serum GGT level was associated with an increased risk for low bone mass compared to tertile 1 (odds ratio, 2.271; 95% confi-
dence interval, 1.340 to 3.850; P=0.002). 
Conclusion: Serum GGT level was inversely associated with BMD in Korean adults. Further study is necessary to fully elucidate 
the mechanism of the inverse relationship.
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INTRODUCTION
γ-Glutamyl transferase (GGT), a well-known marker of chronic 
alcohol consumption and hepatobiliary disease, is abundantly 
expressed in several tissues, particularly those with secretory or 
absorptive functions, such as the kidneys, pancreas, seminal 
vesicles, small intestine, and bile duct [1,2]. A number of studies 
have demonstrated that serum levels of GGT are independently 
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associated with cardiovascular and metabolic disorders such as 
obesity, metabolic syndrome, type 2 diabetes mellitus, coronary 
heart disease, and stroke [3-14], although the mechanism of 
these associations has not been fully elucidated. GGT plays a 
key role in glutathione homeostasis. GGT is located on the outer 
surface of the plasma membrane with its active site exposed to 
the extracellular space [1,2]. As an ectopeptidase, it catalyzes 
degradation of extracellular glutathione to generate its constitu-
ent amino acids including cysteine. These amino acids are taken 
up by the cells and reutilized for de novo synthesis of glutathi-
one, which participates in many biological functions, including 
antioxidant defense, maintenance of intracellular redox status, 
signal transduction, and nutrient metabolism [1,2,15].
 Bone is an active metabolizing tissue, as both bone forma-
tion and resorption occur throughout life. This bone remodel-
ing process, which determines bone mass, is regulated by many 
systemic and local factors such as estrogens, vitamin D, para-
thyroid hormone, bone morphogenetic proteins, receptor acti-
vator for NF-κB-ligand (RANKL), and osteoprotegerin [16]. 
Several in vitro and in vivo studies have demonstrated that 
GGT affects bone metabolism through systemic and local 
mechanisms [17-20]. Both deficiency and excess GGT are in-
volved in the abnormal bone remodeling processes, which re-
sult in decreased bone mass. However, only a few clinical stud-
ies have demonstrated a significant relationship between GGT 
and bone [20]. In the present study, we performed a cross-sec-
tional analysis to investigate whether serum levels of GGT are 
associated with bone mineral density (BMD) in Korean adults.
METHODS
Subjects and data collection
A total of 462 subjects (289 men and 173 women) aged 21 to 
83 years were recruited from the Healthcare Center at the Sev-
erance Hospital, Yonsei University College of Medicine in 
Seoul, Korea, and were included in analyses. All adult Koreans 
were included if they did not meet any of the exclusion criteria, 
including a history of a medical condition known to be associ-
ated with abnormal bone metabolism or to alter bone mass 
such as hyperparathyroidism, rheumatoid arthritis, and chronic 
renal failure; history of hepatobiliary diseases such as liver cir-
rhosis, primary biliary cirrhosis, or viral hepatitis (including 
positivity for serum hepatitis B surface antigen or serum hepa-
titis C antibody); and current use of medications capable of af-
fecting bone and mineral metabolism such as glucocorticoste-
roid, thyroid hormones, sex hormones, selective estrogen re-
ceptor modulators, or bisphosphonates. All subjects completed 
standardized questionnaires about their medical history, includ-
ing past illnesses, family history, current medication, smoking, 
alcohol consumption, exercise, and menopausal status (in 
women). Height, weight, and waist and hip circumference were 
measured while subjects wore light clothing and no shoes. 
Waist circumference was measured midway between the low-
est rib and the iliac crest, and hip circumference was taken over 
the widest part of the gluteal region. Body mass index (BMI) 
was calculated as weight divided by height squared (kg/m2). 
Smokers were defined as those who smoked at the time of the 
study or who had smoked within 5 years. Those who had 
stopped smoking in the last 5 years or more were regarded as 
nonsmokers. Questions about alcohol intake included the type 
of alcoholic beverage and the frequency and amount of alcohol 
consumed on a weekly basis. Based on their answers, amount 
of alcohol consumed per day was calculated in g/day. Regular 
exercisers were defined as those who exercised at least three 
times per week. Women who had not had a menstrual cycle for 
1 year were considered postmenopausal. Hypertension was de-
fined as systolic blood pressure (BP) ≥140 mm Hg or diastolic 
BP ≥90 mm Hg or current use of BP lowering agent. Diabetes 
mellitus was defined as fasting glucose ≥126 mg/dL or hemo-
globin A1c ≥6.5% or current use of a glucose lowering agent. 
Hypercholesterolemia was defined as total cholesterol ≥200 
mg/dL or use of a cholesterol lowering agent. The study proto-
col was approved by the Institutional Review Board of Sever-
ance Hospital, Yonsei University College of Medicine.
BMD measurement 
BMD (g/cm2) measures of the lumbar spine (L1 to L4), femo-
ral neck, and total hip were assessed using dual energy X-ray 
absorptiometry (QDR-4500W, Hologic, Bedford, MA, USA). 
Three subjects (two males, one female) could not be assessed 
for lumbar spine BMD due to prior vertebroplasty. In these 
subjects, only the femoral neck and total hip BMD were used 
as data. The coefficients of variation for these measurements 
were <1.1%. Osteoporosis was defined as BMD of the lumbar 
spine, total hip, or femoral neck that was 2.5 standard devia-
tions (SDs) or more below the mean of a young Korean refer-
ence population (T-score <−2.5), and osteopenia was defined 
as a T-score between −1 and −2.5. 
Biochemical values 
Blood samples were collected from each subject after an over-
night fast. The concentrations of plasma glucose, serum calci-
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um, phosphorus, creatinine, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase, total 
cholesterol, triglycerides, high density lipoprotein cholesterol, 
and low density lipoprotein cholesterol were measured using 
standard laboratory techniques. Serum GGT levels were mea-
sured by an enzymatic method using a Hitachi 7600-110 auto-
mated chemistry analyzer (Hitachi, Tokyo, Japan). 
Statistical analyses
Statistical analyses were carried out using SPSS version 20.0 
(IBM Co., Armonk, NY, USA). Male and female participants 
were divided into tertiles based on serum GGT level. The GGT 
levels in men were higher than those in women. Thus, sex-spe-
cific tertiles of serum GGT were used for analyses. In men, the 
cut-off points were <24 IU/L (tertile 1), 25 to 38 IU/L (tertile 
2), and >39 IU/L (tertile 3). In women, the cut-off points were 
<13 IU/L (tertile 1), 14 to 20 IU/L (tertile 2), and >21 IU/L 
(tertile 3). Demographic and clinical characteristics were ana-
lyzed according to tertiles of serum GGT levels (Table 1). A 
general linear model for a linear trend analysis was used in 
continuous data analyses. The chi-square test for a linear trend 
was used for the categorical data analyses. BMD at the lumbar 
spine, femoral neck, total hip, and BMD T-scores were ana-
lyzed according to tertiles of serum GGT levels (Table 2). 
Analysis of covariance was used to adjust for confounding 
variables. Variables for adjustment included age (years), BMI 
(kg/m2), amount of alcohol consumed (g/day), smoking (yes or 
no), regular exercise (yes or no), hypertension (yes or no), dia-
betes mellitus (yes or no), hypercholesterolemia (yes or no), 
and postmenopausal state (in women; yes or no). Multiple lin-
ear regression analyses for BMD were performed after adjust-
ing for confounding variables (Table 3). The distribution of 
Table 1. Demographic and Clinical Characteristics of Participants according to Tertiles of Serum GGT Levels   
Variable
Men Women
Tertile 1 
(n=100)
Tertile 2 
(n=93)
Tertile 3 
(n=96)
P for trend Tertile 1 
(n=57)
Tertile 2 
(n=58)
Tertile 3 
(n=58)
P for trend
Age, yr 57.2±8.3 55.5±9.0 54.7±7.9 0.037 51.1±10.1 55.7±9.4 58.0±8.8 <0.001
BMI, kg/m2 24.4±2.3 25.4±2.7 25.6±2.9 0.002 21.9±2.7 22.4±3.0 23.6±3.7 0.005
Waist, cm 87.9±7.1 89.6±11.1 91.1±6.9 0.017 77.4±8.4 79.8±8.9 82.8±10.4 0.004
Alcohol, g/day 15.4±21.6 22.2±27.9 38.5±53.5 <0.001 0.2±0.8 1.6±5.6 2.0±8.7 0.122
Smoking 23 (23.0) 45 (48.4) 51 (53.1) <0.001 2 (3.5) 3 (5.2) 5 (8.6) 0.241
Regular exercise 47 (47.0) 28 (30.1) 35 (36.5) 0.124 19 (33.3) 23 (39.7) 13 (22.4) 0.207
Hypertension 40 (40.0) 43 (46.2) 53 (55.2) 0.033 11 (19.3) 18 (31.0) 23 (39.7) 0.018
Diabetes mellitus 22 (22.0) 17 (18.3) 22 (22.9) 0.883 4 (7.0) 5 (8.6) 6 (10.3) 0.527
Hypercholesterolemia 41 (41.0) 43 (46.2) 64 (66.7) <0.001 22 (38.6) 19 (32.8) 34 (58.6) 0.030
SBP, mm Hg 127±14 126±13 128±14 0.557 115±15 118±15 124±15 0.003
DBP, mm Hg 77±10 77±9 80±10 0.056 71±9 73±10 73±8 0.166
FPG, mg/dL 103±22 106±27 107±20 0.296 95±27 94±13 99±22 0.404
HbA1c, % 5.9±0.8 5.8±0.7 5.9±0.5 0.987 5.5±0.4 5.7±0.6 5.8±0.8 0.009
Triglyceride, mg/dL 119±56 142±58 180±95 <0.001 95±49 104±49 146±78 <0.001
HDL-C, mg/dL 47±9 46±11 49±12 0.282 57±12 56±13 55±14 0.410
LDL-C, mg/dL 119±35 114±28 122±37 0.628 115±25 124±23 128±35 0.017
TC, mg/dL 179±33 179±30 193±37 0.004 186±32 191±29 203±39 0.007
AST, mg/dL 22.8±19.0 22.1±6.4 25.6±11.9 0.147 19.4±6.2 21.2±4.8 26.5±9.5 <0.001
ALT, mg/dL 22.2±15.6 26.8±13.7 33.5±20.2 <0.001 15.7±5.6 18.6±6.5 27.8±14.6 <0.001
Creatinine, mg/dL 1.0±0.1 1.0±0.2 1.0±0.2 0.672 0.8±0.1 0.8±0.1 0.8±0.2 0.053
Values are expressed as mean±SD or number (%). Tertiles of serum GGT levels in men: tertile 1, ≤24 IU/L; tertile 2, 25–38 IU/L; tertile 3, ≥39 IU/
L. Tertiles of serum GGT levels in women: tertile 1, ≤13 IU/L; tertile 2, 14–20 IU/L; tertile 3 ≥21 IU/L.  
GGT, γ-glutamyl transferase; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; 
HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol; AST, as-
partate aminotransferase; ALT, alanine aminotransferase.        
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GGT values was right-skewed; therefore, natural log-transfor-
mation was applied. Multiple logistic regression analysis was 
used to evaluate the odds ratios (ORs) and 95% confidence in-
tervals (CIs) of having low bone mass including osteopenia 
and osteoporosis (Table 4). The OR (95% CI) for having low 
bone mass in those who belonged to tertiles 2 and 3 was evalu-
ated compared to those who belonged to tertile 1. All tests were 
two-sided, and P<0.05 was considered significant.
RESULTS
Demographics and clinical characteristics of the participants
The mean±SD age of the participants was 55.8±8.4 years for 
men and 55.0±9.8 for women. The mean±SD BMI was 
25.1±2.7 for men and 22.7±3.2 for women. The mean±SD 
serum level of GGT was 40.5±31.4 IU/L in men and 21.4±
19.0 IU/L in women. The demographic and clinical character-
istics of the participants were compared among the tertiles of 
serum GGT levels in men and women (Table 1). The average 
age of men decreased with increasing serum GGT level from 
tertile 1 to tertile 3, whereas the average age of women in-
creased. In both sexes, the mean values of BMI and waist cir-
cumference increased with serum GGT level from tertile 1 to 
tertile 3. The average amount of alcohol consumed and the per-
centage of participants smoking increased with increasing se-
rum GGT level in men. The prevalence of hypertension and 
hypercholesterolemia also increased with elevating serum GGT 
level in both sexes. Other clinical and biochemical parameters 
are presented in Table 1. 
Associations between serum GGT levels and BMD
Mean BMD values measured at the lumbar spine, femoral 
neck, and total hip were compared among tertiles of serum 
GGT levels (Table 2). Mean BMD values at the lumbar spine 
Table 2. Comparison of BMD among Tertiles of Serum GGT Levels       
Variable
Men Women
Tertile 1 
(n=100)
Tertile 2 
(n=93)
Tertile 3 
(n=96)
P for trend Tertile 1 
(n=57)
Tertile 2 
(n=58)
Tertile 3 
(n=58)
P for trend
LS BMD, g/cm2 1.066±0.013 1.063±0.013 1.022±0.012 0.018 0.986±0.017 0.970±0.017 0.915±0.017 0.004
LS BMD (T-score)
   Model 1a 0.4±0.1 0.3±0.1 0.0±0.1 0.011 –0.2±0.1 –0.3±0.1 –0.8±0.1 0.004
   Model 2b 0.4±0.1 0.3±0.1 0.0±0.1 0.006 –0.2±0.1 –0.3±0.1 –0.8±0.1 0.006
   Model 3c 0.3±0.1 0.4±0.1 0.0±0.1 0.047 –0.3±0.1 –0.3±0.1 –0.7±0.1 0.022
   Model 4d 0.3±0.1 0.4±0.1 0.0±0.1 0.050 –0.3±0.1 –0.3±0.1 –0.7±0.1 0.025
FN BMD, g/cm2 0.814±0.011 0.816±0.011 0.811±0.011 0.826 0.748±0.013 0.718±0.013 0.692±0.013 0.003
FN BMD (T-score)
   Model 1a –0.3±0.1 –0.2±0.1 –0.3±0.1 0.793 –0.5±0.1 –0.8±0.1 –1.0±0.1 0.003
   Model 2b –0.2±0.1 –0.3±0.1 –0.3±0.1 0.117 –0.6±0.1 –0.7±0.1 –1.0±0.1 0.009
   Model 3c –0.2±0.1 –0.2±0.1 –0.4±0.1 0.163 –0.6±0.1 –0.8±0.1 –1.0±0.1 0.020
   Model 4d –0.2±0.1 –0.2±0.1 –0.4±0.1 0.188 –0.6±0.1 –0.8±0.1 –1.0±0.1 0.021
TH BMD, g/cm2 0.963±0.012 0.970±0.013 0.952±0.012 0.542 0.858±0.016 0.816±0.015 0.796±0.015 0.005
TH BMD (T-score)
   Model 1a 0.2±0.1 0.2±0.1 0.1±0.1 0.468 0.1±0.1 –0.3±0.1 –0.5±0.1 0.006
   Model 2b 0.3±0.1 0.2±0.1 0.0±0.1 0.042 0.0±0.1 –0.3±0.1 –0.5±0.1 0.007
   Model 3c 0.3±0.1 0.2±0.1 0.0±0.1 0.038 0.0±0.1 –0.3±0.1 –0.4±0.1 0.023
   Model 4d 0.3±0.1 0.2±0.1 0.0±0.1 0.056 0.0±0.1 –0.3±0.1 –0.4±0.1 0.026
Values are expressed as mean±SE. Tertiles of serum GGT level in men: tertile 1, ≤24 IU/L; tertile 2, 25–38 IU/L; tertile 3, ≥39 IU/L. Tertiles of se-
rum GGT level in women: tertile 1, ≤13 IU/L; tertile 2, 14–20 IU/L; tertile 3 ≥21 IU/L.    
BMD, bone mineral density; GGT, γ-glutamyl transferase; LS, lumbar spine; FN, femoral neck; TH, total hip.    
aModel 1: no adjustment; bModel 2: adjusted for age and body mass index; cModel 3: adjusted as in model 2 plus amount of alcohol consumed, smok-
ing, regular exercise, and postmenopausal state (in women); dModel 4: adjusted as in model 3 plus hypertension, diabetes mellitus, and hypercholes-
terolemia.
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decreased as serum GGT level increased from tertile 1 to 3 in 
both sexes. Mean BMD values at the femoral neck and total 
hip also decreased with increasing serum GGT level in women. 
The BMD T-scores were compared between the different ter-
tiles in men and women. As shown in Table 2, the BMD T-
scores at all sites decreased with increasing GGT level from 
tertile 1 to tertile 3 in women, which remained statistically sig-
nificant even after adjusting for confounders (model 1 to 4). In 
men, the BMD T-scores at lumbar spine significantly decreased 
with increasing serum GGT level (model 1). Adjustment for 
possible predictors of BMD such as age, BMI, amount of alco-
hol consumed, smoking, and regular exercise made the associa-
tions between serum GGT levels and BMD T-scores at the 
lumbar spine and total hip statistically significant (model 2, 3). 
Even after further adjustment for hypertension, diabetes melli-
tus, and hypercholesterolemia, the associations between serum 
GGT levels and BMD T-scores at the lumbar spine and total 
hip showed a tendency toward inverse association (model 4). 
Multiple linear regression analysis for BMD was performed 
with log-transformed serum GGT level as covariates. In this 
model, log-transformed serum GGT level was inversely associ-
ated with BMD (Table 3).
Multiple logistic regression analysis for low bone mass
The multiple logistic regression analysis results for low bone 
mass including osteopenia and osteoporosis are presented in 
Table 4. Age, sex, BMI, amount of alcohol consumed, smok-
ing, regular exercise, and tertile of serum GGT level were in-
cluded as covariates. In this analysis, age, sex, BMI, and serum 
GGT level were associated with low bone mass. Age and BMI 
were independently associated with low bone mass with ORs 
(95% CI) of 1.053 (1.027 to 1.079) and 0.850 (0.788 to 0.918), 
respectively. Compared to men, the OR (95% CI) for low bone 
mass was 2.210 (1.326 to 3.683) for women. Tertile 3 of the se-
rum GGT level was associated with increased risk for low bone 
mass compared to tertile 1 (OR, 2.271; 95% CI, 1.340 to 3.850; 
P=0.002), but tertile 2 of serum GGT level was not associated 
with low bone mass in this analysis. 
DISCUSSION
In the present study, we showed that serum GGT level was in-
versely associated with BMD in Korean adults after adjusting 
Table 3. Multiple Linear Regression Analyses between Serum 
GGT Levels and BMD    
Ln GGT
Men Women
β P value β P value
LS BMD
   Model 1a –0.163 0.006 –0.306 <0.001
   Model 2b –0.184 0.002 –0.316 <0.001
   Model 3c –0.146 0.016 –0.314 <0.001
   Model 4d –0.147 0.017 –0.311 <0.001
FN BMD
   Model 1a –0.034 0.569 –0.271 <0.001
   Model 2b –0.119 0.037 –0.269 <0.001
   Model 3c –0.113 0.052 –0.276 <0.001
   Model 4d –0.111 0.061 –0.278 <0.001
TH BMD
   Model 1a –0.065 0.268 –0.287 <0.001
   Model 2b –0.148 0.009 –0.306 <0.001
   Model 3c –0.152 0.008 –0.307 <0.001
   Model 4d –0.149 0.011 –0.307 <0.001
GGT, γ-glutamyl transferase; BMD, bone mineral density; Ln GGT, 
log-transformed value of serum GGT level; LS, lumbar spine; FN, 
femoral neck; TH, total hip.    
aModel 1: no adjustment; bModel 2: adjusted for age and body mass 
index; cModel 3: adjusted as in model 2 plus amount of alcohol con-
sumed, smoking, regular exercise, and postmenopausal state (in wom-
en); dModel 4: adjusted as in model 3 plus hypertension, diabetes mel-
litus, and hypercholesterolemia.   
Table 4. Multiple Logistic Regression Analysis for Low Bone 
Mass
Variable OR (95% CI) P value
Age 1.053 (1.027–1.079) <0.001
Women 2.210 (1.326–3.683) 0.002
Body mass index 0.850 (0.788–0.918) <0.001
Amount of alcohol consumed 0.992 (0.982–1.001) 0.086
Smoking 1.386 (0.804–2.391) 0.241
Regular exercise 0.745 (0.481–1.152) 0.185
Serum GGT level
   Tertile 1 Reference
   Tertile 2 0.981 (0.584–1.651) 0.944
   Tertile 3 2.271 (1.340–3.850) 0.002
Low bone mass: the lowest bone mineral density T-score among those 
measured at lumbar spine, femoral neck, and total hip ≤−1.0. Tertiles 
of serum GGT levels in men: tertile 1, ≤24 IU/L; tertile 2, 25–38 IU/
L; tertile 3, ≥39 IU/L. Tertiles of serum GGT level in women: tertile 1, 
≤13 IU/L; tertile 2, 14–20 IU/L; tertile 3 ≥21 IU/L.  
OR, odds ratio; CI, confidence interval; GGT, γ-glutamyl transferase.
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for confounders such as alcohol consumption, which is a well-
known factor associated with both elevated serum GGT level 
and low bone mass. Furthermore, we also demonstrated that the 
highest tertile of serum GGT level (≥39 IU/L in men and ≥21 
IU/L in women) was associated with an increased risk for low 
bone mass including osteopenia and osteoporosis. These results 
suggest that GGT might negatively affect bone metabolism. 
 Several in vitro and in vivo studies have demonstrated that 
GGT can affect bone metabolism through systemic and local 
mechanisms [17-20]. It was shown that the GGT protein puri-
fied from rat kidney effectively stimulates osteoclast formation 
in mouse bone marrow culture possibly via expression of 
RANKL in marrow stromal cells [17]. In addition, transgenic 
mice overexpressing GGT either systemically or locally in skel-
etal tissue exhibit osteopenia and microstructural deterioration, 
which was attributable to both increased bone resorption and 
decreased bone formation as evidenced by histomorphometry 
[18]. Bone marrow cells from these mice exhibited significantly 
higher expression of transcription factors essential for osteo-
clastogenesis such as c-fos, c-jun, and NFATc1. In that study, 
mutated GGT devoid of enzyme activity was also as potent as 
the wild-type molecule for inducing osteoclast formation, sug-
gesting that GGT acts not as an enzyme but as a cytokine. GGT-
deficient mice also exhibit a marked decrease in bone density 
along with other abnormalities including growth retardation, 
early mortality, and cataracts [19,21]. Osteopenia in GGT-defi-
cient mice was attributable to both increased bone resorption 
and decreased bone formation. In these mice, restoration of cys-
teine deficiency by N-acetylcysteine supplementation amelio-
rated skeletal abnormalities, suggesting that abnormal cysteine 
metabolism in GGT-deficient mice might have caused the ab-
normal skeletal phenotype [19]. A clinical study also suggested 
GGT as a marker of bone resorption in human subjects. It 
showed that urinary GGT excretion was highly correlated with 
deoxypyridinoline, an established biochemical marker of bone 
resorption, in a survey of postmenopausal women [20]. 
 Taken together, both deficiency and excess GGT seem to be 
involved in abnormal bone metabolism, which results in de-
creased bone mass. GGT seems to affect bone formation main-
ly through its enzymatic activity on glutathione metabolism, 
and also affects bone resorption as a cytokine independent of 
enzymatic activity. However, GGT deficiency is a very rare au-
tosomal recessive disease in a clinical setting, and only a few 
patients with this disease have been reported worldwide [22-
26]. In contrast, patients with excess GGT can easily be found, 
particularly among those who chronically consume alcohol or 
those with hepatobiliary diseases. Therefore, excess GGT rather 
than deficiency is clinically relevant to the general health con-
dition. In the present study, we also think excess GGT may ex-
plain the inverse relationship between serum GGT and BMD.
 As stated above, GGT also plays an important role in the in-
tracellular antioxidant defense by maintaining glutathione ho-
meostasis [27]. Cells increase expression of glutathione in re-
sponse to oxidative stress, as this tripeptide removes oxidants 
[28,29]. Expression of several enzymes involved in glutathione 
homeostasis including GGT must be modulated to upregulate 
glutathione synthesis. Several experimental studies have dem-
onstrated that GGT expression is increased in response to oxida-
tive stress [30-32]. This result suggests that increased GGT con-
centration could be a marker of oxidative stress that is known to 
play a role in the development of many pathological conditions 
such as cancer, diabetes mellitus, atherosclerosis, neurodegen-
erative diseases, and rheumatoid arthritis [33,34]. Oxidative 
stress is also known to affect bone metabolism and have an in-
verse association with bone mass [35,36]. Several experimental 
studies have shown that oxidative stress enhances osteoclastic 
activity [37], while inhibiting osteoblastic differentiation [38]. 
Therefore, serum GGT level as a marker of oxidative stress may 
have an inverse relationship with bone mass, as found in the 
present study. Abnormal bone metabolism associated with liver 
diseases may also explain the association between bone and 
GGT in this study. Serum level of GGT is a well-known marker 
of hepatobiliary disease. In the present study, serum levels of 
AST and ALT also increased with elevating serum GGT level. 
There have been studies that demonstrated chronic liver diseas-
es may have negative effects on bone [39]. 
 The present study had several limitations. First, because it 
was a cross-sectional observational study, the associations 
found are not proof of causal relationships and might be con-
founded by many unmeasured and unaccounted for variables 
even after multiple adjustments. Second, we did not measure 
estrogen levels, which may play a role in the relationship be-
tween serum GGT and BMD, particularly in women. In a pre-
vious study, oral contraceptive use and menopause were associ-
ated with increased serum GGT levels [40], suggesting that es-
trogens, a well-known determinant of bone mass, might also be 
a factor that affects serum GGT levels. Third, we did not mea-
sure bone turnover markers. Therefore, we could not determine 
how serum GGT is clinically associated with bone turnover.
 In conclusion, we showed that serum GGT level was in-
versely associated with BMD in Korean adults and that excess 
GGT level was associated with increased risk for low bone 
Choi HS, et al.
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mass. Further studies are necessary to investigate the effect of 
GGT on bone among those with increased serum GGT level 
such as individuals with chronic alcoholism or hepatobiliary 
diseases. 
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